Supplementary Table – First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status
收藏数据链接：
官方服务：
资源简介：
<b>Supplementary Table 1</b>. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status <i>The reasons for dose reduction</i>
提供机构：
Taylor & Francis创建时间：
2021-11-11
